{"id":350134,"date":"2026-11-17T14:10:23","date_gmt":"2026-11-17T08:40:23","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350134"},"modified":"2026-11-17T14:10:23","modified_gmt":"2026-11-17T08:40:23","slug":"alkem-laboratories-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/","title":{"rendered":"Alkem Laboratories Analyst Review 2027: Sales Up 14%, Profit Down 12%, and a Tax Rate That Tripled"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Alkem Laboratories Stock Snapshot (16 Nov 2026 close)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b95,136<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b95,933.50 \/ \u20b94,811<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b961,456 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 29.4 vs 40.7<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b94,552 crore (consolidated)<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b9675 crore (consolidated)<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Alkem Laboratories analyst review 2027<\/strong> shows a business growing faster than its profit line. Q2 FY27 revenue rose 13.8% to \u20b94,552 crore and EBITDA rose 11.3% to \u20b91,025 crore, but profit after tax fell 11.7% to \u20b9675 crore because the effective tax rate jumped to about 33% from 13%. Brokers are divided: Nomura (Buy, \u20b96,890) sits at the top, Motilal Oswal (Neutral, \u20b95,770) and ICICI Securities (Neutral, \u20b95,840) in the middle, and BOBCAPS (Sell, \u20b94,638) at the bottom. At \u20b95,136, the stock trades closer to its 52-week low than its high.<\/p>\n<\/div>\n<p>The <strong>Alkem Laboratories analyst review 2027<\/strong> begins with a quarter where the operating story and the reported profit pointed in opposite directions. For anyone following the <strong>Alkem Laboratories share price target 2027<\/strong>, the September 2026 quarter, reported on 12 November, showed revenue up 13.8% and <strong>EBITDA<\/strong> up 11.3%, while net profit fell 11.7% because of a much higher tax charge.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/alkem\/alkem-laboratories-ltd-share-price-today\">Alkem Laboratories<\/a> closed at \u20b95,136 on 16 November 2026, about 13% below its 52-week high of \u20b95,933.50 and just 7% above its low of \u20b94,811. This Alkem Laboratories analyst review 2027 covers the <strong>brokerage<\/strong> spread, the quarter, how the company earns, and the issues that will shape the <strong>Alkem Laboratories stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=alkem-laboratories-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Brokerage_Views_in_the_Alkem_Laboratories_Analyst_Review_2027\" title=\"Brokerage Views in the Alkem Laboratories Analyst Review 2027\">Brokerage Views in the Alkem Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Q2_FY27_Results_in_the_Alkem_Laboratories_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Alkem Laboratories Analyst Review 2027\">Q2 FY27 Results in the Alkem Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#How_Alkem_Laboratories_Makes_Money\" title=\"How Alkem Laboratories Makes Money\">How Alkem Laboratories Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Growth_Triggers_in_the_Alkem_Laboratories_Analyst_Review_2027\" title=\"Growth Triggers in the Alkem Laboratories Analyst Review 2027\">Growth Triggers in the Alkem Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Key_Risks_in_the_Alkem_Laboratories_Analyst_Review_2027\" title=\"Key Risks in the Alkem Laboratories Analyst Review 2027\">Key Risks in the Alkem Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Alkem_Laboratories_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Alkem Laboratories Analyst Review 2027: Stock at a Glance\">Alkem Laboratories Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#What_to_Watch_After_the_Alkem_Laboratories_Analyst_Review_2027\" title=\"What to Watch After the Alkem Laboratories Analyst Review 2027\">What to Watch After the Alkem Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Final_Word_on_the_Alkem_Laboratories_Analyst_Review_2027\" title=\"Final Word on the Alkem Laboratories Analyst Review 2027\">Final Word on the Alkem Laboratories Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#What_does_the_Alkem_Laboratories_analyst_review_2027_show\" title=\"What does the Alkem Laboratories analyst review 2027 show?\">What does the Alkem Laboratories analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#What_is_the_Alkem_Laboratories_share_price_target_2027_from_brokerages\" title=\"What is the Alkem Laboratories share price target 2027 from brokerages?\">What is the Alkem Laboratories share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Why_did_profit_fall_in_the_Alkem_Laboratories_analyst_review_2027_quarter\" title=\"Why did profit fall in the Alkem Laboratories analyst review 2027 quarter?\">Why did profit fall in the Alkem Laboratories analyst review 2027 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#How_did_India_sales_perform_in_the_Alkem_Laboratories_analyst_review_2027\" title=\"How did India sales perform in the Alkem Laboratories analyst review 2027?\">How did India sales perform in the Alkem Laboratories analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#Is_Alkem_Laboratories_expensive_according_to_the_Alkem_Laboratories_analyst_review_2027\" title=\"Is Alkem Laboratories expensive, according to the Alkem Laboratories analyst review 2027?\">Is Alkem Laboratories expensive, according to the Alkem Laboratories analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#What_risks_does_the_Alkem_Laboratories_analyst_review_2027_highlight\" title=\"What risks does the Alkem Laboratories analyst review 2027 highlight?\">What risks does the Alkem Laboratories analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alkem-laboratories-analyst-review\/#What_should_investors_track_after_the_Alkem_Laboratories_analyst_review_2027\" title=\"What should investors track after the Alkem Laboratories analyst review 2027?\">What should investors track after the Alkem Laboratories analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Brokerage_Views_in_the_Alkem_Laboratories_Analyst_Review_2027\"><\/span><strong>Brokerage Views in the Alkem Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table lists targets traced to dated reports. None was issued after the 12 November results, so these are the latest verified positions.<\/p>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Nomura<\/td>\n<td>Buy<\/td>\n<td>\u20b96,890<\/td>\n<td>May 2026<\/td>\n<\/tr>\n<tr>\n<td>ICICI Securities<\/td>\n<td>Neutral<\/td>\n<td>\u20b95,840<\/td>\n<td>May 2026<\/td>\n<\/tr>\n<tr>\n<td>Motilal Oswal Financial Services<\/td>\n<td>Neutral<\/td>\n<td>\u20b95,770<\/td>\n<td>August 2026<\/td>\n<\/tr>\n<tr>\n<td>Choice Institutional Equities<\/td>\n<td>Add<\/td>\n<td>\u20b95,755<\/td>\n<td>May 2026<\/td>\n<\/tr>\n<tr>\n<td>BOB Capital Markets (BOBCAPS)<\/td>\n<td>Sell<\/td>\n<td>\u20b94,638<\/td>\n<td>May 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Motilal Oswal&#8217;s August note captures the middle view. It called Q1 FY27 a strong margin-led beat with good momentum in chronic therapies, but said investments in new businesses would weigh on FY27 earnings and left limited upside at 27 times forward earnings. Nomura is more optimistic, pointing to double-digit India growth and a lower tax rate in earlier guidance. BOBCAPS sees the stock as already fully valued.<\/p>\n<p>So the <strong>Alkem Laboratories analyst review 2027<\/strong> spans about 10% downside to 34% upside. The tax surprise in Q2 is likely to be the main topic of any revised <strong>brokerage<\/strong> notes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Alkem_Laboratories_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Alkem Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27<\/th>\n<th>Q2 FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue from Operations<\/td>\n<td>\u20b94,552 crore<\/td>\n<td>\u20b94,001 crore<\/td>\n<td>+13.8%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>\u20b91,025 crore<\/td>\n<td>\u20b9921 crore<\/td>\n<td>+11.3%<\/td>\n<\/tr>\n<tr>\n<td>Profit After Tax (after minority)<\/td>\n<td>\u20b9675 crore<\/td>\n<td>\u20b9765 crore<\/td>\n<td>-11.7%<\/td>\n<\/tr>\n<tr>\n<td>India Sales<\/td>\n<td>\u20b93,028 crore<\/td>\n<td>\u20b92,766 crore<\/td>\n<td>+9.5%<\/td>\n<\/tr>\n<tr>\n<td>International Sales<\/td>\n<td>\u20b91,454 crore<\/td>\n<td>\u20b91,189 crore<\/td>\n<td>+22.3%<\/td>\n<\/tr>\n<tr>\n<td>Effective Tax Rate<\/td>\n<td>about 33.2%<\/td>\n<td>about 13.0%<\/td>\n<td>+20 pts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The tax line explains almost everything. A jump in the effective tax rate to about 33% from 13% turned <strong>EBITDA<\/strong> growth into a profit decline. Alkem had earlier benefited from lower tax on certain operations, so the step-up hurts comparisons for several quarters. There was also a one-time gain of about \u20b935 crore in the quarter.<\/p>\n<p>The underlying business was healthy. In the Alkem Laboratories analyst review 2027 numbers, chronic therapies grew 22.4%, well ahead of Indian pharma market growth of about 16%. US sales rose 2.4% to \u20b9783 crore despite pricing pressure, and non-US international sales jumped 58% to \u20b9671 crore, or about 29% without the Occlutech acquisition.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Alkem_Laboratories_Makes_Money\"><\/span><strong>How Alkem Laboratories Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>India branded generics:<\/strong> about 68% of sales. Alkem is a leader in acute therapies such as anti-infectives and pain management, and is growing in chronic areas like diabetes and cardiology.<\/li>\n<li><strong>United States:<\/strong> generic medicines sold through distributors, a market with steady price erosion.<\/li>\n<li><strong>Other international markets:<\/strong> branded and generic sales in Latin America, Europe, Asia and Africa, now including Occlutech&#8217;s medical devices.<\/li>\n<li><strong>New businesses:<\/strong> biosimilars through the Enzene subsidiaries and contract development and manufacturing.<\/li>\n<\/ul>\n<p>India is the profit engine, which is why the Alkem Laboratories analyst review 2027 debate often centres on whether domestic growth can beat the market by enough.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Alkem_Laboratories_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Alkem Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Chronic portfolio:<\/strong> growth of 22.4% in Q2 shows Alkem gaining share in higher-value therapies.<\/li>\n<li><strong>Non-US exports:<\/strong> 58% growth, helped by Occlutech, diversifies away from the US.<\/li>\n<li><strong>Margin guidance:<\/strong> management guided an <strong>EBITDA<\/strong> margin of 20% to 21% for FY27, and Q2 came in at about 22.5%.<\/li>\n<li><strong>Biosimilars:<\/strong> Enzene is a longer-term option that could lift growth once launches scale.<\/li>\n<li><strong>New leadership:<\/strong> Dr Amrut Naik took over as CEO, and the board appointed a new CFO with the Q2 results.<\/li>\n<\/ul>\n<p>Alkem is also a member of the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index, so sector flows affect its price.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Alkem_Laboratories_Analyst_Review_2027\"><\/span><strong>Key Risks in the Alkem Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Higher tax:<\/strong> a tax rate near 33% will keep profit growth below <strong>EBITDA<\/strong> growth until the base adjusts.<\/li>\n<li><strong>India growth:<\/strong> 9.5% domestic growth trailed the market&#8217;s 16%, mainly because acute therapies were slower.<\/li>\n<li><strong>US pricing:<\/strong> 2.4% growth in the US shows continued price erosion.<\/li>\n<li><strong>New business costs:<\/strong> Motilal Oswal expects investments in biosimilars and other new areas to depress FY27 earnings.<\/li>\n<li><strong>Leadership transition:<\/strong> a new CEO and CFO in the same year bring execution risk.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Alkem Laboratories With Pharma Peers on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alkem_Laboratories_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Alkem Laboratories Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (16 Nov 2026 close)<\/td>\n<td>\u20b95,136<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b95,933.50 \/ \u20b94,811<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b961,456 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM) vs Industry<\/td>\n<td>29.4 vs 40.7<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>4.13<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>\u20b91,243<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>13.91%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.16<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>1.03%<\/td>\n<\/tr>\n<tr>\n<td>FY26 Revenue \/ Net Profit<\/td>\n<td>\u20b915,296 crore \/ \u20b92,353 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>P\/E<\/strong> of about 29 is below the pharma industry average of about 41, which is one reason the Alkem Laboratories analyst review 2027 shows more Neutral and Add calls than Sell calls.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>51.20%<\/td>\n<td>49.70%<\/td>\n<td>-1.50 pts<\/td>\n<\/tr>\n<tr>\n<td>Foreign Institutions (FII)<\/td>\n<td>9.48%<\/td>\n<td>10.32%<\/td>\n<td>+0.84 pts<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>21.93%<\/td>\n<td>22.82%<\/td>\n<td>+0.89 pts<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>17.40%<\/td>\n<td>17.15%<\/td>\n<td>-0.25 pts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>promoter<\/strong> group, the Singh family, cut its holding to just under 50%, while both foreign and domestic institutions added. <strong>Promoter<\/strong> selling of this size is not unusual for a family-run company, but it is worth tracking alongside the leadership change.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Alkem_Laboratories_Analyst_Review_2027\"><\/span><strong>What to Watch After the Alkem Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Tax guidance:<\/strong> management&#8217;s view on the FY27 and FY28 effective tax rate.<\/li>\n<li><strong>India growth versus market:<\/strong> management had aimed for 100 to 150 basis points above market growth.<\/li>\n<li><strong>Margin delivery:<\/strong> whether the 20% to 21% FY27 margin guide is raised.<\/li>\n<li><strong>Biosimilar progress:<\/strong> launches and partnerships at Enzene.<\/li>\n<li><strong>Revised targets:<\/strong> fresh notes that will reset the Alkem Laboratories share price target 2027 range.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Alkem_Laboratories_Analyst_Review_2027\"><\/span><strong>Final Word on the Alkem Laboratories Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Alkem Laboratories analyst review 2027<\/strong> separates a healthy operating quarter from a disappointing profit line. Revenue and <strong>EBITDA<\/strong> grew at double digits, chronic therapies and exports were strong, and margins beat guidance. A tax rate that rose to about 33% is what pushed profit down.<\/p>\n<p>Brokers were already split before the results, from \u20b94,638 to \u20b96,890. With the stock near the lower end of its range and a <strong>P\/E<\/strong> below the industry, the <strong>Alkem Laboratories stock outlook 2027<\/strong> will depend on whether India growth recovers and tax clarity arrives. Univest does not give a buy or sell call on the stock.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Alkem_Laboratories_analyst_review_2027_show\"><\/span><strong>What does the Alkem Laboratories analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows Q2 FY27 revenue up 13.8% to \u20b94,552 crore and EBITDA up 11.3% to \u20b91,025 crore. Profit after tax fell 11.7% to \u20b9675 crore because the effective tax rate rose to about 33%. Brokerage views range from Sell to Buy.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alkem_Laboratories_share_price_target_2027_from_brokerages\"><\/span><strong>What is the Alkem Laboratories share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Nomura has a Buy with \u20b96,890, ICICI Securities a Neutral with \u20b95,840 and Choice an Add with \u20b95,755, all from May 2026. Motilal Oswal has a Neutral with \u20b95,770 from August 2026, and BOBCAPS a Sell with \u20b94,638. Against \u20b95,136, the range runs from about 10% downside to 34% upside.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_profit_fall_in_the_Alkem_Laboratories_analyst_review_2027_quarter\"><\/span><strong>Why did profit fall in the Alkem Laboratories analyst review 2027 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The effective tax rate jumped to about 33.2% from about 13.0% a year earlier. That turned 11.3% EBITDA growth into an 11.7% profit decline. The quarter also included a one-time gain of about \u20b935 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_India_sales_perform_in_the_Alkem_Laboratories_analyst_review_2027\"><\/span><strong>How did India sales perform in the Alkem Laboratories analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India sales rose 9.5% to \u20b93,028 crore and made up about 68% of total sales. Chronic therapies grew 22.4%, well above market growth of about 16%. Slower acute therapies held back overall domestic growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alkem_Laboratories_expensive_according_to_the_Alkem_Laboratories_analyst_review_2027\"><\/span><strong>Is Alkem Laboratories expensive, according to the Alkem Laboratories analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Alkem trades at a P\/E of about 29.4, below the pharma industry figure of about 40.7. Its price to book is 4.13 and return on equity is 13.91%. Debt to equity of just 0.16 adds balance sheet comfort.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Alkem_Laboratories_analyst_review_2027_highlight\"><\/span><strong>What risks does the Alkem Laboratories analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A higher tax rate, India growth that trailed the market and US price erosion are the main risks. Motilal Oswal expects new-business investments to weigh on FY27 earnings. The company also has a new CEO and a new CFO in the same year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Alkem_Laboratories_analyst_review_2027\"><\/span><strong>What should investors track after the Alkem Laboratories analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track tax-rate guidance, India growth against the market and delivery on the 20% to 21% margin guide. Biosimilar progress at Enzene is a longer-term factor. Fresh brokerage notes after the 12 November 2026 results will update the target range.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Alkem Laboratories analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows Q2 FY27 revenue up 13.8% to \u20b94,552 crore and EBITDA up 11.3% to \u20b91,025 crore. Profit after tax fell 11.7% to \u20b9675 crore because the effective tax rate rose to about 33%. Brokerage views range from Sell to Buy.\"}},{\"@type\":\"Question\",\"name\":\"What is the Alkem Laboratories share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nomura has a Buy with \u20b96,890, ICICI Securities a Neutral with \u20b95,840 and Choice an Add with \u20b95,755, all from May 2026. Motilal Oswal has a Neutral with \u20b95,770 from August 2026, and BOBCAPS a Sell with \u20b94,638. Against \u20b95,136, the range runs from about 10% downside to 34% upside.\"}},{\"@type\":\"Question\",\"name\":\"Why did profit fall in the Alkem Laboratories analyst review 2027 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The effective tax rate jumped to about 33.2% from about 13.0% a year earlier. That turned 11.3% EBITDA growth into an 11.7% profit decline. The quarter also included a one-time gain of about \u20b935 crore.\"}},{\"@type\":\"Question\",\"name\":\"How did India sales perform in the Alkem Laboratories analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"India sales rose 9.5% to \u20b93,028 crore and made up about 68% of total sales. Chronic therapies grew 22.4%, well above market growth of about 16%. Slower acute therapies held back overall domestic growth.\"}},{\"@type\":\"Question\",\"name\":\"Is Alkem Laboratories expensive, according to the Alkem Laboratories analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alkem trades at a P\/E of about 29.4, below the pharma industry figure of about 40.7. Its price to book is 4.13 and return on equity is 13.91%. Debt to equity of just 0.16 adds balance sheet comfort.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Alkem Laboratories analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"A higher tax rate, India growth that trailed the market and US price erosion are the main risks. Motilal Oswal expects new-business investments to weigh on FY27 earnings. The company also has a new CEO and a new CFO in the same year.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Alkem Laboratories analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track tax-rate guidance, India growth against the market and delivery on the 20% to 21% margin guide. Biosimilar progress at Enzene is a longer-term factor. Fresh brokerage notes after the 12 November 2026 results will update the target range.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alkem grew Q2 FY27 revenue 13.8% and EBITDA 11.3%, yet profit fell 11.7% as its tax rate jumped to 33%. We review five brokerage targets from \u20b94,638 to \u20b96,890, the India and export businesses, and the risks for 2027.<\/p>\n","protected":false},"author":35,"featured_media":350133,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,10617,4341,6686],"class_list":["post-350134","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-alkem-laboratories","tag-analyst-review","tag-pharmaceuticals"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350133"],"rank_math_title":["Alkem Laboratories Share Price Target 2027: Views"],"rank_math_description":["Alkem Laboratories analyst review 2027: Q2 FY27 revenue up 14%, profit down 12% on tax, India and export trends, broker targets and share price target 2027."],"rank_math_focus_keyword":["Alkem Laboratories analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/alkem-laboratories-analyst-review-2027-sales-up-14-profit-down-12-and-a-tax-rate.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350134"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350134\/revisions"}],"predecessor-version":[{"id":350135,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350134\/revisions\/350135"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350133"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}